C
Creasallis develops CreaTap, a patented, plug-and-play technology that modifies antibody therapeutics to enhance their penetration into solid tumours. This engineering solution addresses the limitation of poor drug diffusion within the tumour microenvironment for monoclonal antibodies, ADCs, and bispecifics. The technology aims to improve therapeutic efficacy by enabling deeper drug delivery and potentially creating new intellectual property opportunities for existing biologics.
Updated 4 months ago
Funding
$980K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Creasallis develops CreaTap, a patented, plug-and-play technology that modifies antibody therapeutics to enhance their penetration into solid tumours. This engineering solution addresses the limitation of poor drug diffusion within the tumour microenvironment for monoclonal antibodies, ADCs, and bispecifics. The technology aims to improve therapeutic efficacy by enabling deeper drug delivery and potentially creating new intellectual property opportunities for existing biologics.